{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06212583",
            "orgStudyIdInfo": {
                "id": "HP-00108148"
            },
            "secondaryIdInfos": [
                {
                    "id": "GCC 23100",
                    "type": "OTHER",
                    "domain": "University of Maryland Medical System"
                }
            ],
            "organization": {
                "fullName": "University of Maryland, Baltimore",
                "class": "OTHER"
            },
            "briefTitle": "High-Risk Metachronous Oligometastatic Prostate Cancer Trial",
            "officialTitle": "A Randomized Trial of High-risK metachroNous oligometastatIc Prostate Cancer With hiGh-risk Mutations Treated witH meTastasiS Directed Therapy and Niraparib/Abiraterone Acetate and Prednisone (KNIGHTS)",
            "acronym": "KNIGHTS",
            "therapeuticArea": [
                "Oncology and Hematology",
                "Other"
            ],
            "study": "high-risk-metachronous-oligometastatic-prostate-cancer-trial"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-04",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-04-17",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2028-12-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2029-12-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-12-14",
            "studyFirstSubmitQcDate": "2024-01-16",
            "studyFirstPostDateStruct": {
                "date": "2024-01-19",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-04-19",
            "lastUpdatePostDateStruct": {
                "date": "2024-04-23",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Jason Molitoris, MD PhD",
                "investigatorTitle": "Principal Investigator",
                "investigatorAffiliation": "University of Maryland, Baltimore"
            },
            "leadSponsor": {
                "name": "University of Maryland, Baltimore",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "Janssen Scientific Affairs, LLC",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this research study is to compare the effects, good and/or bad, of using the standard of care treatment, hormonal therapy + Stereotactic Ablative Radiation (SABR) to the metastatic lesions, compared to standard of care and addition of 6-months of niraparib/abiraterone acetate combination pills and prednisone for participants with recurrent metastatic prostate cancer.",
            "detailedDescription": "In this trial all participants will be randomized to one of the two groups. You will be randomly assigned (by chance, like the flip of a coin) to one of the two groups: 1: Standard of care treatment (hormonal therapy + SABR to the metastatic lesions) or 2: Standard of care treatment + 6-months of niraparib/abiraterone acetate combination pills and prednisone. Participants in both groups will receive rectal swabs and various blood tests to assess circulating tumor cells, genomic sequencing, and tumor markers. Both groups will also participate in quality-of-life surveys"
        },
        "conditionsModule": {
            "conditions": [
                "Prostate Cancer",
                "Oligometastatic Disease"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 88,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Androgen deprivation therapy + Stereotactic ablative radiation",
                    "type": "ACTIVE_COMPARATOR",
                    "interventionNames": [
                        "Radiation: Stereotactic ablative radiation therapy (SABR)",
                        "Drug: Androgen deprivation therapy (ADT)"
                    ]
                },
                {
                    "label": "Androgen deprivation therapy + Stereotactic ablative radiation + niraparib/abiraterone acetate",
                    "type": "ACTIVE_COMPARATOR",
                    "interventionNames": [
                        "Drug: niraparib/abiraterone acetate",
                        "Radiation: Stereotactic ablative radiation therapy (SABR)",
                        "Drug: Androgen deprivation therapy (ADT)"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "niraparib/abiraterone acetate",
                    "description": "Patients on Arm 2 to receive drug for 6 months",
                    "armGroupLabels": [
                        "Androgen deprivation therapy + Stereotactic ablative radiation + niraparib/abiraterone acetate"
                    ]
                },
                {
                    "type": "RADIATION",
                    "name": "Stereotactic ablative radiation therapy (SABR)",
                    "description": "Both arms will receive SABR",
                    "armGroupLabels": [
                        "Androgen deprivation therapy + Stereotactic ablative radiation",
                        "Androgen deprivation therapy + Stereotactic ablative radiation + niraparib/abiraterone acetate"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Androgen deprivation therapy (ADT)",
                    "description": "All ADT is provided as best prescribed for patient per their medical oncologist.",
                    "armGroupLabels": [
                        "Androgen deprivation therapy + Stereotactic ablative radiation",
                        "Androgen deprivation therapy + Stereotactic ablative radiation + niraparib/abiraterone acetate"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "PSA (Prostate Specific Antigen) evaluation at the 18-month progression of both treatment arms",
                    "description": "PSA evaluation of progression at 18-month PSA , defined as PSA \\> 0.2 ng/mL in patients initially treated with radical prostatectomy and greater than nadir + 2 ng/mL for patients initially treated with definitive radiation, with testosterone \\>100 ng/dl of men who have oligometastatic castration-sensitive prostate cancer with high-risk mutations (TP53, BRCA1/2, PALB2, ATM, BRIP1, CHEK2, FANCA, RAD51B, RAD54L, MUTYH) treated with ADT + SABR MDT (6-mos) versus ADT + SABR MDT + niraparib/abiraterone acetate and prednisone (6-mos).",
                    "timeFrame": "18 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Treatment-related adverse events of both treatment arms",
                    "description": "Number of participants with treatment-related adverse events from ADT+ SABR MDT (6-mos) vs ADT + SABR MDT + niraparib/abiraterone acetate and prednisone (6-mos) in patients with metachronous oligometastatic CSPC disease.",
                    "timeFrame": "4 years"
                },
                {
                    "measure": "Local control at 18 months after ADT+ SABR MDT (6-mos) vs ADT + SABR MDT + niraparib/abiraterone acetate and prednisone (6-mos) in patients with metachronous oligometastatic Castrate Specific Prostate Cancer (CSPC) disease.",
                    "description": "Local control will be evaluated through clinical assessment and periodic imaging.",
                    "timeFrame": "18 months"
                },
                {
                    "measure": "Time to locoregional progression, time to distant progression, time to new metastasis, radiographic progression-free survival and duration of response after randomization",
                    "description": "Progression will be assessed for time to locoregional progression, time to distant progression, time to new metastasis, radiographic progression-free survival and duration of response after randomization.",
                    "timeFrame": "4 years"
                },
                {
                    "measure": "Quality-of-life measured through EPIC tool following completion of ADT+ SABR MDT (6-mos) vs ADT + SABR MDT + niraparib/abiraterone acetate and prednisone (6-mos).",
                    "description": "EPIC quality of life tool will be used to assess quality of life following treatment. Averages will be taken for each section in the survey (Urinary Function, Bowel Function, Sexual Function, and Hormonal function).",
                    "timeFrame": "4 years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. \u226518 years of age (or the local legal age of consent).\n2. Patient must have at least one and up to three asymptomatic metastatic tumor(s) of the bone, soft tissue, or extra-pelvic nodal region each \\< 5 cm or \\< 250 cm3 that develop within the past 6-months that are seen on imaging. A nodal lesion is defined to include nodal conglomerates located in the same nodal chain such that they can be treated in one SABR field. Up to five lesions are allowed on advanced functional imaging such as fluciclovine (Axumin), choline or Prostate Specific Membrane Antigen (PSMA) PET-CT scan.\n\n   1. CT or MRI scan within 6 months of enrollment\n   2. Bone scan within 6 months of enrollment\n   3. Fluciclovine (Axumin), choline, or PSMA PET-CT scan within 6 months of enrollment (PET-CT scan is reasonable for study entry imaging as an alternative to CT/MRI scan and bone scan)\n3. Must have a high-risk pathogenic mutation (TP53, BRCA1/2, PALB2, ATM, BRIP1, CHEK2, FANCA, RAD51B, RAD54L, MUTYH) by next generation sequencing. ATM mutation enrollment will be capped at 5% of the overall population.\n4. Histologic confirmation of prostate adenocarcinoma (primary or metastatic tumor).\n5. Patient may have had prior systemic therapy and/or ADT so long as testosterone is \\> 100 ng/dl prior to enrollment\n6. PSA \\> 0.5 but \\<50 at enrollment.\n7. Prostate Specific Antigen Doubling Time (PSADT) \\< 15 months\n8. Baseline testosterone \\> 100 ng/dl\n9. Patient must have a life expectancy \u2265 12 months.\n10. Patient must have an ECOG performance status \u2264 2.\n11. Adequate hematologic, renal, and hepatic function at screening defined as follows:\n\n    \u2022 Absolute neutrophil count \u22651.5 x 109/L\n\n    \u2022 Hemoglobin \u22659.0 g/dL, independent of transfusions for at least 28 days\n    * Platelet count \u2265100 x 109/L\n    * Creatinine \\<2 x upper limit of normal (ULN)\n    * Serum potassium \u22653.5 mmol/L\n    * Serum total bilirubin \u22641.5\u00d7 ULN or direct bilirubin \u22641 x ULN (Note: In participants with Gilbert's syndrome, if total bilirubin is \\>1.5 \u00d7 ULN, measure direct and indirect bilirubin, and if direct bilirubin is \u22641.5 \u00d7 ULN, participant may be eligible)\n    * AST or ALT \u22643 \u00d7 ULN\n12. Patient must have the ability to understand and the willingness to sign a written informed consent document\n13. Able to swallow the study medication tablets whole.\n14. While on study medication and for 4 months following the last dose of study medication, a male participant must agree to use condom and an adequate contraception method for female partner (WOCBP) A male participant must agree not to donate sperm while on study treatment and for a minimum of 4 months following the last dose of study medication.\n\n<!-- -->\n\n1. Castration-resistant prostate cancer (CRPC).\n2. Prior radiation therapy to an overlapping site of a target lesion that would preclude further radiation therapy\n3. Spinal cord compression or impending spinal cord compression.\n4. Suspected intracranial and/or liver metastases (\\>10 mm in largest axis).\n5. Patient receiving any other investigational agents.\n6. Inability to receive any form of systemic therapy in the opinion of a treating medical oncologist.\n7. Unable to lie flat during or tolerate PET/MRI, PET/CT or SABR.\n8. Radiographical evidence of cranial parenchymal metastasis.\n9. Active second primary malignancy; AML/MDS in medical history.\n10. Uncontrolled hypertension and myocardial infarction/PE/cardiac failure in last 6 months.\n11. Prior treatment with PARP inhibitor\n12. Refusal to sign informed consent.\n13. Pathological finding consistent with small cell or neuroendocrine carcinoma of the prostate.\n14. History of adrenal dysfunction\n15. Long-term use of systemically administered corticosteroids (\\>5mg of prednisone or the equivalent) during the study is not allowed. Short-term use (\u22644 weeks, including taper) and locally administered steroids (eg, inhaled, topical, ophthalmic, and intra-articular) are allowed, if clinically indicated.\n16. Active malignancies (ie, progressing or requiring treatment change in the last 24 months) other than the disease being treated under study. The only allowed exceptions are:\n\n    * non-muscle invasive bladder cancer.\n    * skin cancer (non-melanoma or melanoma) treated within the last 24 months that is considered completely cured.\n    * malignancy that is considered cured with minimal risk of recurrence.\n    * History or current diagnosis of MDS/AML.\n17. Current evidence within 6 months prior to randomization of any of the following:\n\n    \u2022 severe/unstable angina, myocardial infarction, symptomatic congestive heart failure,\n\n    \u2022 clinically significant arterial or venous thromboembolic events (ie. Pulmonary embolism), or clinically significant ventricular arrhythmias.\n18. Presence of sustained uncontrolled hypertension (systolic blood pressure \\>160 mm Hg or diastolic blood pressure \\>100 mm Hg). Participants with a history of hypertension are allowed, provided that blood pressure is controlled to within these limits by an antihypertensive treatment.\n19. Known allergies, hypersensitivity, or intolerance to the excipients of niraparib/abiraterone acetate tablets\n20. Current evidence of any medical condition that would make prednisone use contraindicated.\n21. Received an investigational intervention (including investigational vaccines) or used an invasive investigational medical device within 30 days before the planned first dose of study medication.\n22. Participants who have had the following \u226428 days prior to randomization:\n\n    \u2022 A transfusion (platelets or red blood cells);\n\n    \u2022 Hematopoietic growth factors;\n\n    \u2022 Major surgery\n23. Human immunodeficiency virus positive participants with 1 or more of the following:\n\n    \u2022 Not receiving highly active antiretroviral therapy or on antiretroviral therapy for less than 4 weeks.\n    * Receiving antiretroviral therapy that may interfere with the study medication\n    * CD4 count \\<350 at screening.\n    * An acquired immunodeficiency syndrome-defining opportunistic infection within 6 months of the start of screening.\n    * Human immunodeficiency virus load \\>400 copies/mL\n24. Active or symptomatic viral hepatitis or chronic liver disease; encephalopathy, ascites or bleeding disorders secondary to hepatic dysfunction.\n25. Moderate or severe hepatic impairment (Class B and C per Child-Pugh classification system.",
            "healthyVolunteers": false,
            "sex": "MALE",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Phuoc Tran, MD",
                    "role": "CONTACT",
                    "phone": "410-328-6080",
                    "email": "phuoc.tran@umm.edu"
                },
                {
                    "name": "Caitlin Eggleston",
                    "role": "CONTACT",
                    "phone": "410-328-7586",
                    "email": "caitlineggleston@umm.edu"
                }
            ],
            "locations": [
                {
                    "facility": "University of Maryland Greenebaum Cancer Center",
                    "status": "RECRUITING",
                    "city": "Baltimore",
                    "state": "Maryland",
                    "zip": "21201",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Phuoc Tran, MD",
                            "role": "CONTACT",
                            "phone": "410-328-6080"
                        },
                        {
                            "name": "Caitlin Eggleston",
                            "role": "CONTACT",
                            "phone": "410-328-7586"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.29038,
                        "lon": -76.61219
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000011471",
                    "term": "Prostatic Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000005834",
                    "term": "Genital Neoplasms, Male"
                },
                {
                    "id": "D000014565",
                    "term": "Urogenital Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000005832",
                    "term": "Genital Diseases, Male"
                },
                {
                    "id": "D000091662",
                    "term": "Genital Diseases"
                },
                {
                    "id": "D000091642",
                    "term": "Urogenital Diseases"
                },
                {
                    "id": "D000011469",
                    "term": "Prostatic Diseases"
                },
                {
                    "id": "D000052801",
                    "term": "Male Urogenital Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M14335",
                    "name": "Prostatic Neoplasms",
                    "asFound": "Prostate Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12307",
                    "name": "Neoplasm Metastasis",
                    "relevance": "LOW"
                },
                {
                    "id": "M8946",
                    "name": "Genital Neoplasms, Male",
                    "relevance": "LOW"
                },
                {
                    "id": "M17315",
                    "name": "Urogenital Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M2876",
                    "name": "Genital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8944",
                    "name": "Genital Diseases, Male",
                    "relevance": "LOW"
                },
                {
                    "id": "M2875",
                    "name": "Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14333",
                    "name": "Prostatic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27095",
                    "name": "Male Urogenital Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000069501",
                    "term": "Abiraterone Acetate"
                },
                {
                    "id": "C000545685",
                    "term": "Niraparib"
                },
                {
                    "id": "D000000728",
                    "term": "Androgens"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000065088",
                    "term": "Steroid Synthesis Inhibitors"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000006727",
                    "term": "Hormone Antagonists"
                },
                {
                    "id": "D000006730",
                    "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000065607",
                    "term": "Cytochrome P-450 Enzyme Inhibitors"
                },
                {
                    "id": "D000006728",
                    "term": "Hormones"
                },
                {
                    "id": "D000067856",
                    "term": "Poly(ADP-ribose) Polymerase Inhibitors"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M14121",
                    "name": "Prednisone",
                    "relevance": "LOW"
                },
                {
                    "id": "M289466",
                    "name": "Niraparib",
                    "asFound": "PEEP",
                    "relevance": "HIGH"
                },
                {
                    "id": "M451",
                    "name": "Abiraterone Acetate",
                    "asFound": "Unilateral",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4059",
                    "name": "Androgens",
                    "asFound": "Percutaneous Coronary Intervention",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M9789",
                    "name": "Hormones",
                    "relevance": "LOW"
                },
                {
                    "id": "M9788",
                    "name": "Hormone Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M30537",
                    "name": "Cytochrome P-450 Enzyme Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M205",
                    "name": "Poly(ADP-ribose) Polymerase Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Infl",
                    "name": "Anti-Inflammatory Agents"
                },
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}